A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab

Figure 1

Patient’s platelet counts relative to the time courses of his treatment before (a) and after (b) hospitalization. In (a) and (b), the Y-axis and the X-axis represent platelet counts and the number of days before and after the first treatment of evolocumab, respectively. Day 0 indicates the initial day of evolocumab therapy. The periods of atorvastatin and evolocumab treatment are indicated above the graph in (a). PT, platelet transfusions (two injections); HI, high-dose immunoglobulin (25 g per day for 5 consecutive days); E, eltrombopag (thin line, 12.5 mg; thick line, 25 mg per day, respectively); P, prednisone (starting with 1 mg/kg).

(a)

(b)